Healthcare provider profile · identity verified

Matthew J Gibfried, MD

Allopathic & Osteopathic Physicians|Psychiatry & Neurology|Psychiatry · SAINT LOUIS, MO · NPI 1104887728

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Matthew J Gibfried, MD received $83.76 in general payments during 2025 across 1 reported records.

E.R. Squibb & Sons, L.L.C. accounted for 100.0% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 1 associated product.

E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 339 claims for Eliquis by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$83.76

1 reported records · 1 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
E.R. Squibb & Sons, L.L.C.	Unresolved — no canonical attribution shown	$83.76	100.0%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$83.76	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
COBENFY Normalized: cobenfy	Drug	E.R. Squibb & Sons, L.L.C.	$83.76	1	2025
Source payment records 2025-07-29 · E.R. Squibb & Sons, L.L.C. · $83.76 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference	2025	ELIQUIS open payments reported associated product	CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713	Eliquis · 2024 Exact normalized brand match · 1 Part D row	339	50

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	738	99
Quetiapine Fumarate	Quetiapine Fumarate	576	95
Sertraline Hcl	Sertraline Hcl	560	89
Levothyroxine Sodium	Levothyroxine Sodium	557	75
Amlodipine Besylate	Amlodipine Besylate	390	71
Potassium Chloride	Potassium Chloride	379	64
Omeprazole	Omeprazole	376	42
Gabapentin	Gabapentin	353	55
Trazodone Hcl	Trazodone Hcl	340	83
Eliquis	Apixaban	339	50
Rosuvastatin Calcium	Rosuvastatin Calcium	323	50
Mirtazapine	Mirtazapine	322	63
Pantoprazole Sodium	Pantoprazole Sodium	319	59
Furosemide	Furosemide	313	63
Donepezil Hcl	Donepezil Hcl	307	49
Tamsulosin Hcl	Tamsulosin Hcl	269	32
Duloxetine Hcl	Duloxetine Hcl	262	47
Torsemide	Torsemide	255	48
Metoprolol Tartrate	Metoprolol Tartrate	238	37
Lisinopril	Lisinopril	235	34
Losartan Potassium	Losartan Potassium	228	37
Escitalopram Oxalate	Escitalopram Oxalate	223	39
Metoprolol Succinate	Metoprolol Succinate	221	36
Clonazepam	Clonazepam	213	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	205	62
Memantine Hcl	Memantine Hcl	205	35
Simvastatin	Simvastatin	204	23
Buspirone Hcl	Buspirone Hcl	192	33
Famotidine	Famotidine	188	27
Olanzapine	Olanzapine	170	32
Spironolactone	Spironolactone	166	29
Clopidogrel	Clopidogrel Bisulfate	133	18
Fluoxetine Hcl	Fluoxetine Hcl	126	25
Allopurinol	Allopurinol	121	18
Fluticasone Propionate	Fluticasone Propionate	120	34
Metformin Hcl	Metformin Hcl	119	15
Alprazolam	Alprazolam	111	30
Citalopram Hbr	Citalopram Hydrobromide	110	19
Finasteride	Finasteride	110	15
Lorazepam	Lorazepam	105	24
Pravastatin Sodium	Pravastatin Sodium	96	16
Risperidone	Risperidone	93	19
Divalproex Sodium	Divalproex Sodium	91	22
Methenamine Hippurate	Methenamine Hippurate	89	12
Montelukast Sodium	Montelukast Sodium	88	suppressed
Carvedilol	Carvedilol	87	20
Aripiprazole	Aripiprazole	81	21
Carbidopa-Levodopa	Carbidopa/Levodopa	81	11
Lamotrigine	Lamotrigine	78	11
Hydrochlorothiazide	Hydrochlorothiazide	75	12
Venlafaxine Hcl Er	Venlafaxine Hcl	75	14
Bupropion Xl	Bupropion Hcl	74	16
Lovastatin	Lovastatin	74	suppressed
Prednisone	Prednisone	67	35
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	66	11
Myrbetriq	Mirabegron	62	suppressed
Xarelto	Rivaroxaban	62	suppressed
Hydralazine Hcl	Hydralazine Hcl	61	14
Levetiracetam	Levetiracetam	61	suppressed
Tradjenta	Linagliptin	59	suppressed
Bupropion Hcl Sr	Bupropion Hcl	58	suppressed
Alendronate Sodium	Alendronate Sodium	57	suppressed
Topiramate	Topiramate	55	suppressed
Atenolol	Atenolol	52	suppressed
Folic Acid	Folic Acid	52	suppressed
Ropinirole Hcl	Ropinirole Hcl	52	suppressed
Loperamide	Loperamide Hcl	51	27
Meloxicam	Meloxicam	51	13
Tramadol Hcl	Tramadol Hcl	51	14
Diclofenac Sodium	Diclofenac Sodium	49	suppressed
Mupirocin	Mupirocin	47	18
Haloperidol	Haloperidol	46	suppressed
Synthroid	Levothyroxine Sodium	45	suppressed
Glipizide	Glipizide	43	suppressed
Nystatin	Nystatin	43	20
Cephalexin	Cephalexin	42	19
Lansoprazole	Lansoprazole	42	suppressed
Diazepam	Diazepam	41	suppressed
Ketoconazole	Ketoconazole	41	13
Timolol Maleate	Timolol Maleate	41	suppressed
Albuterol Sulfate Hfa	Albuterol Sulfate	40	20
Lacosamide	Lacosamide	39	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	38	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	38	19
Jardiance	Empagliflozin	37	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	36	32
Olmesartan Medoxomil	Olmesartan Medoxomil	36	suppressed
Warfarin Sodium	Warfarin Sodium	36	suppressed
Midodrine Hcl	Midodrine Hcl	35	suppressed
Nitrofurantoin	Nitrofurantoin Macrocrystal	35	suppressed
Primidone	Primidone	35	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	35	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	33	suppressed
Nebivolol Hcl	Nebivolol Hcl	33	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	33	15
Cefdinir	Cefdinir	32	32
Bethanechol Chloride	Bethanechol Chloride	30	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	30	suppressed
Basaglar Kwikpen U-100	Insulin Glargine,hum.Rec.Anlog	29	suppressed
Ezetimibe	Ezetimibe	29	suppressed
Glipizide Er	Glipizide	29	suppressed
Linzess	Linaclotide	29	suppressed
Paroxetine Hcl	Paroxetine Hcl	29	suppressed
Autoshield Duo Pen Needle	Pen Needle,dual Safety,diabetc	28	suppressed
Alcohol Swabs	Alcohol Antiseptic Pads	27	suppressed
Hydrocortisone	Hydrocortisone	27	11
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	27	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	27	suppressed
Ventolin Hfa	Albuterol Sulfate	27	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	26	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	26	23
Tolterodine Tartrate Er	Tolterodine Tartrate	26	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	25	suppressed
Clonidine Hcl	Clonidine Hcl	25	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	25	suppressed
Glycopyrrolate	Glycopyrrolate	25	suppressed
Symbicort	Budesonide/Formoterol Fumarate	25	suppressed
Clozapine	Clozapine	24	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	24	13
Januvia	Sitagliptin Phosphate	24	suppressed
Oxcarbazepine	Oxcarbazepine	24	suppressed
Vyvanse	Lisdexamfetamine Dimesylate	24	suppressed
Bumetanide	Bumetanide	23	suppressed
Chlorhexidine Gluconate	Chlorhexidine Gluconate	23	suppressed
Methylphenidate Hcl	Methylphenidate Hcl	23	suppressed
Baclofen	Baclofen	22	suppressed
Diltiazem Hcl	Diltiazem Hcl	22	suppressed
Amiodarone Hcl	Amiodarone Hcl	21	suppressed
Calcitriol	Calcitriol	21	suppressed
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	21	suppressed
Ibandronate Sodium	Ibandronate Sodium	21	suppressed
Lithium Carbonate	Lithium Carbonate	21	suppressed
Lithium Carbonate Er	Lithium Carbonate	21	suppressed
Prazosin Hcl	Prazosin Hcl	21	suppressed
Labetalol Hcl	Labetalol Hcl	20	suppressed
Latanoprost	Latanoprost	20	suppressed
Medroxyprogesterone Acetate	Medroxyprogesterone Acetate	20	suppressed
Memantine Hcl Er	Memantine Hcl	20	suppressed
Sevelamer Carbonate	Sevelamer Carbonate	20	suppressed
Azelastine Hcl	Azelastine Hcl	19	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	19	suppressed
Metolazone	Metolazone	19	suppressed
Nyamyc	Nystatin	19	suppressed
Oxycodone Hcl	Oxycodone Hcl	19	suppressed
Digoxin	Digoxin	18	suppressed
Oxycontin	Oxycodone Hcl	18	suppressed
Amitriptyline Hcl	Amitriptyline Hcl	17	suppressed
Ammonium Lactate	Ammonium Lactate	17	suppressed
Benztropine Mesylate	Benztropine Mesylate	17	suppressed
Farxiga	Dapagliflozin Propanediol	17	suppressed
Zonisamide	Zonisamide	17	suppressed
Clomipramine Hcl	Clomipramine Hcl	16	suppressed
Clotrimazole	Clotrimazole	16	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	16	suppressed
Lactulose	Lactulose	16	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	16	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	16	suppressed
Dutasteride	Dutasteride	15	suppressed
Fenofibrate	Fenofibrate	15	suppressed
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	15	suppressed
Metformin Hcl Er	Metformin Hcl	15	suppressed
Tizanidine Hcl	Tizanidine Hcl	15	suppressed
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	15	suppressed
Verapamil Er	Verapamil Hcl	15	suppressed
Amoxicillin	Amoxicillin	14	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	14	suppressed
Glimepiride	Glimepiride	14	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	14	suppressed
Lidocaine	Lidocaine	14	suppressed
Propranolol Hcl	Propranolol Hcl	14	suppressed
Terazosin Hcl	Terazosin Hcl	14	suppressed
Atropine Sulfate	Atropine Sulfate	13	suppressed
Azithromycin	Azithromycin	13	11
Fesoterodine Fumarate Er	Fesoterodine Fumarate	13	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	13	suppressed
Nifedipine Er	Nifedipine	13	suppressed
Novofine Autocover	Pen Needle, Diabetic, Safety	13	suppressed
Prolia	Denosumab	13	suppressed
Rivastigmine	Rivastigmine Tartrate	13	suppressed
Solifenacin Succinate	Solifenacin Succinate	13	suppressed
Tamoxifen Citrate	Tamoxifen Citrate	13	suppressed
Acetazolamide	Acetazolamide	12	suppressed
Colchicine	Colchicine	12	suppressed
Dilantin	Phenytoin Sodium Extended	12	suppressed
Eszopiclone	Eszopiclone	12	suppressed
Ezetimibe-Simvastatin	Ezetimibe/Simvastatin	12	suppressed
Ondansetron Hcl	Ondansetron Hcl	12	11
Ondansetron Odt	Ondansetron	12	11
Phenytoin Sodium Extended	Phenytoin Sodium Extended	12	suppressed
Tresiba Flextouch U-100	Insulin Degludec	12	suppressed
Ultra-Fine Short Pen Needle	Pen Needle, Diabetic	12	suppressed
Valsartan	Valsartan	12	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	12	suppressed
Benazepril Hcl	Benazepril Hcl	11	suppressed
Clobetasol Propionate	Clobetasol Propionate	11	suppressed
Clorazepate Dipotassium	Clorazepate Dipotassium	11	suppressed
Fosinopril Sodium	Fosinopril Sodium	11	suppressed
Ingrezza	Valbenazine Tosylate	11	suppressed
Isosorbide Dinitrate	Isosorbide Dinitrate	11	suppressed
Klor-Con 8	Potassium Chloride	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$83.76 · 1 records	E.R. Squibb & Sons, L.L.C.	COBENFY	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error